Quanticate Expands their Global Operations for Biostatistics and Programming in Clinical Trials
Bangalore and North Carolina facilities look to expand staff after the award of two large FSPs
Quanticate, a leading global data-focused clinical research organization (CRO) today announced the expansion of its global resources to support clinical trials. The region most affected is Bangalore and North Carolina, particularly in the areas of biostatistics and statistical programming, following the award of large functional service provision (FSP) contracts with two industry-leading pharmaceutical companies.
Quanticate is looking to significantly grow its resource capabilities and will be recruiting staff over a range of roles in biostatistics and statistical programming across all levels of seniority throughout 2014 based upon its overall pipeline of work. Opportunities will include graduate to principal roles in India and the US as well as other global locations.
"The expansion of our current customers coupled with the addition of new partnerships and two large-scale FSPs, has resulted in the need to expand our resource base across all our locations,” explained Daniel Chapple, Chief Commercial Officer. “This expansion will also enable us to extend our presence to other cities in India and we are currently in the process of identifying facilities,” continued Chapple.
The addition of two new partnerships means that Quanticate is now supporting biostatistics and programming for six of the Top 8 pharmaceutical companies and has gained extensive experience in successfully supporting companies in strategic partnerships within the data field. “Many companies are seeing the benefits from companies that can offer global expertise in their niche fields rather than using full service CROs whose primary focus is monitoring and project management,” explains David Underwood, CEO of Quanticate. Underwood continues, “This approach can also drastically reduce operational oversight on the client side where successful partnerships are built on quality, performance, trust and understanding. It also means clients gain from the big benefit of having subject experts supporting their programs of work.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
